MX2020011089A - Compuestos antiproliferacion y usos de los mismos. - Google Patents
Compuestos antiproliferacion y usos de los mismos.Info
- Publication number
- MX2020011089A MX2020011089A MX2020011089A MX2020011089A MX2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- antiproliferation
- cancer
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661719P | 2018-04-24 | 2018-04-24 | |
| PCT/US2019/028607 WO2019209759A1 (en) | 2018-04-24 | 2019-04-23 | Antiproliferation compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011089A true MX2020011089A (es) | 2020-11-06 |
Family
ID=66655429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011089A MX2020011089A (es) | 2018-04-24 | 2019-04-23 | Compuestos antiproliferacion y usos de los mismos. |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10815225B2 (https=) |
| EP (2) | EP4043460B1 (https=) |
| JP (2) | JP7304892B2 (https=) |
| KR (1) | KR102813581B1 (https=) |
| CN (1) | CN112236428B (https=) |
| AR (1) | AR114496A1 (https=) |
| AU (1) | AU2019261308B2 (https=) |
| BR (1) | BR112020020940A2 (https=) |
| CA (1) | CA3098335A1 (https=) |
| CY (1) | CY1125433T1 (https=) |
| DK (2) | DK3784666T3 (https=) |
| ES (2) | ES2919572T3 (https=) |
| FI (1) | FI4043460T3 (https=) |
| HR (2) | HRP20241163T1 (https=) |
| HU (2) | HUE067936T2 (https=) |
| IL (2) | IL278142B2 (https=) |
| LT (1) | LT3784666T (https=) |
| MX (1) | MX2020011089A (https=) |
| PL (2) | PL4043460T3 (https=) |
| PT (2) | PT4043460T (https=) |
| RS (1) | RS63281B1 (https=) |
| SG (1) | SG11202009500QA (https=) |
| SI (1) | SI3784666T1 (https=) |
| SM (1) | SMT202200308T1 (https=) |
| TW (1) | TWI813673B (https=) |
| WO (1) | WO2019209759A1 (https=) |
| ZA (1) | ZA202006071B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2919572T3 (es) | 2018-04-24 | 2022-07-27 | Merck Patent Gmbh | Compuestos antiproliferación y usos de los mismos |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020236834A1 (en) * | 2019-05-20 | 2020-11-26 | Seshadri Raju | Modified z stents for iliac vein stenting |
| US20230046892A1 (en) | 2019-12-20 | 2023-02-16 | Bayer Aktiengesellschaft | Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof |
| WO2024073502A1 (en) * | 2022-09-28 | 2024-04-04 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
| WO2025223536A1 (zh) * | 2024-04-26 | 2025-10-30 | 正大天晴药业集团股份有限公司 | 稠合双环化合物及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| AR073354A1 (es) | 2008-07-31 | 2010-11-03 | Genentech Inc | Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer. |
| AR076014A1 (es) * | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| BR112012012905A2 (pt) * | 2009-12-04 | 2017-03-01 | Hoffmann La Roche | derivados de difenil azepina como inibidores da reabsorção de monoamina |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20180118721A1 (en) * | 2015-02-13 | 2018-05-03 | Merck Patent Gmbh | Pyrimidine derivatives |
| ES2919572T3 (es) | 2018-04-24 | 2022-07-27 | Merck Patent Gmbh | Compuestos antiproliferación y usos de los mismos |
-
2019
- 2019-04-23 ES ES19726792T patent/ES2919572T3/es active Active
- 2019-04-23 PT PT221619620T patent/PT4043460T/pt unknown
- 2019-04-23 PT PT197267925T patent/PT3784666T/pt unknown
- 2019-04-23 BR BR112020020940-6A patent/BR112020020940A2/pt active Search and Examination
- 2019-04-23 ES ES22161962T patent/ES2987356T3/es active Active
- 2019-04-23 LT LTEPPCT/US2019/028607T patent/LT3784666T/lt unknown
- 2019-04-23 HR HRP20241163TT patent/HRP20241163T1/hr unknown
- 2019-04-23 HU HUE22161962A patent/HUE067936T2/hu unknown
- 2019-04-23 KR KR1020207033873A patent/KR102813581B1/ko active Active
- 2019-04-23 AR ARP190101062A patent/AR114496A1/es unknown
- 2019-04-23 RS RS20220537A patent/RS63281B1/sr unknown
- 2019-04-23 WO PCT/US2019/028607 patent/WO2019209759A1/en not_active Ceased
- 2019-04-23 PL PL22161962.0T patent/PL4043460T3/pl unknown
- 2019-04-23 MX MX2020011089A patent/MX2020011089A/es unknown
- 2019-04-23 SG SG11202009500QA patent/SG11202009500QA/en unknown
- 2019-04-23 EP EP22161962.0A patent/EP4043460B1/en active Active
- 2019-04-23 HU HUE19726792A patent/HUE058746T2/hu unknown
- 2019-04-23 AU AU2019261308A patent/AU2019261308B2/en active Active
- 2019-04-23 HR HRP20220710TT patent/HRP20220710T1/hr unknown
- 2019-04-23 PL PL19726792.5T patent/PL3784666T3/pl unknown
- 2019-04-23 IL IL278142A patent/IL278142B2/en unknown
- 2019-04-23 IL IL301501A patent/IL301501B2/en unknown
- 2019-04-23 JP JP2020559394A patent/JP7304892B2/ja active Active
- 2019-04-23 DK DK19726792.5T patent/DK3784666T3/da active
- 2019-04-23 SM SM20220308T patent/SMT202200308T1/it unknown
- 2019-04-23 US US16/391,419 patent/US10815225B2/en active Active
- 2019-04-23 SI SI201930251T patent/SI3784666T1/sl unknown
- 2019-04-23 EP EP19726792.5A patent/EP3784666B1/en active Active
- 2019-04-23 CN CN201980036896.XA patent/CN112236428B/zh active Active
- 2019-04-23 CA CA3098335A patent/CA3098335A1/en active Pending
- 2019-04-23 FI FIEP22161962.0T patent/FI4043460T3/fi active
- 2019-04-23 TW TW108114146A patent/TWI813673B/zh active
- 2019-04-23 DK DK22161962.0T patent/DK4043460T3/da active
-
2020
- 2020-08-27 US US17/004,109 patent/US11440907B1/en active Active
- 2020-09-30 ZA ZA2020/06071A patent/ZA202006071B/en unknown
-
2022
- 2022-06-10 CY CY20221100409T patent/CY1125433T1/el unknown
- 2022-09-07 US US17/930,352 patent/US12195453B2/en active Active
-
2023
- 2023-06-05 JP JP2023092450A patent/JP2023101824A/ja active Pending
-
2024
- 2024-11-08 US US18/941,447 patent/US20250188070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202403923B (en) | Heterocyclic compounds as immunomodulators | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| MX2023008954A (es) | Inhibidores de los receptores erbb. | |
| PH12021500014A1 (en) | Fused ring compounds | |
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| EP4520328A3 (en) | Heterocyclic compounds as immunomodulators | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2023010411A (es) | Inhibidores de erbb/btk. | |
| MX2023009185A (es) | Compuestos de benzamida. | |
| NZ752250A (en) | Compounds, devices, and uses thereof | |
| EP4442695A3 (en) | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| MX379459B (es) | Inhibidores de bromodominios. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| GEAP202415883A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2023009060A (es) | Antagonistas de gpr84 y usos de estos. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX394245B (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| MX2020013729A (es) | Compuestos de cianotriazol y usos de los mismos. | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| WO2016112304A8 (en) | Furoquinolinediones as inhibitors of tdp2 |